Havencrest Capital Management has made a majority investment in Tekton Research

Tekton Research

Founded in 2006 and headquartered in Austin, Texas, Tekton Research is a leading clinical trial site network partnering with global pharmaceutical companies and CROs with 23 sites across Texas, Colorado, Georgia, Kansas and Oklahoma. Tekton conducts clinical trials for a wide array of pharmaceutical and device products across several therapeutic areas, including vaccines, infectious disease, neurology, endocrinology, immunology and dermatology, among others. Tekton is a market leader in patient access, enrollment and retention due to the dedication of its superb principal investigators and clinical research coordinators. For more information, please visit www.tektonresearch.com.

The Deal

Havencrest Capital Management, a Dallas-based healthcare private equity (PE) firm, is pleased to announce its majority investment in Tekton. In partnership, Havencrest and Tekton intend to expand the company’s network of talented investigators and new embedded sites, improve clinical trial access for underrepresented patient communities, grow its expertise across therapeutic areas and continue delivering high-quality data to its valued clients. Lincoln International acted as the exclusive financial advisor to Havencrest, leveraging its extensive expertise and track record in outsourced pharmaceutical services.

Our Perspective

Tekton is a premier clinical trial network employing an integrated strategy across embedded and hybrid sites. In a high-growth market with growing demand for speed and volume of quality patients in clinical studies, the company has built a reputation of dependability, clinical expertise and patient relationships. We expect Tekton’s partnership with Havencrest to help grow the company’s network capabilities and further establish Tekton’s leading market position.

Havencrest Capital Management

Havencrest is an investment manager of healthcare-focused PE funds with approximately $600 million of assets under management. Havencrest comprises a leading team of investment professionals, operating partners and senior advisors, including many of the nation’s leading healthcare entrepreneurs, corporate executives and public policy experts. With its unique approach to partnering with founder-owned healthcare companies with EBITDA between $3 million – $15+ million, the Havencrest team has a successful track record in building leading companies that are changing the way healthcare is delivered in America. For more information, please visit www.havencrest.com.

Share: